Clinical trials: Narcolepsy Type 2
- Condition Narcolepsy Type 2
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Narcolepsy Type 1, Narcolepsy Type 2
Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year.
- Trial name
- HYPNOS (NCT07299097)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 402 people
- Sponsor
- Takeda
Narcolepsy Type 2
A Study of TAK-861 in Participants With Narcolepsy Type 2
The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT).
- Trial name
- NCT05687916
- Testing
- TAK-861 2 mg, TAK-861 2 mg and 5 mg
- Where
- 56 sites in United States, Australia and 10 more
- Volunteers
- 71 people
- Sponsor
- Takeda